Miriam Englander Paschalis Ilios, MD
Retina Specialist · Boston, MANPI 1184853129
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 46.2% of the total. That places this record below the midpoint for retina specialist clinicians in MA, where the typical reported total is $806.
Across 7 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$78
- Dompe US, Inc.$31
- Bausch & Lomb, A Division Of Bausch Health US, LLC$24
- ANI Pharmaceuticals, Inc.$19
- Novartis$17
What the payments were for
- Food & beverage$170100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 3 | $78 |
| Dompe US, Inc. | 1 | $31 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
How this compares
$170 in reported general payments places this provider in the 20th percentile of 26 retina specialist providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 22 | $5,324 |
| Prednisolone Acetate | 141 | $4,487 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,174 |
| Brimonidine Tartrate | 12 | $657 |
| Diclofenac Sodium | 55 | $588 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 24 | $545 |
| Ofloxacin | 49 | $511 |
| ErythromycinErythromycin Base | 43 | $427 |
| Ketorolac Tromethamine | 29 | $410 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 15 | $157 |
| Timolol Maleate | 13 | $109 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Boston
- Jeffrey HeierBoston$1.5M
- Andre WitkinBoston$23K
- Chirag ShahBoston$14K
- Brian BalliosBoston$3K
- Ilya LeskovBoston$2K
- Siamak ShokrollahiBoston$806
- Omar AbdelalBoston$806
- Xiang WerdichBoston$686
- Mohamed ElmasryBoston$190
- Tina ClearyBoston$184
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.